Multimodality Therapy for Recurrent High Risk Prostate Cancer: A Phase II Study.

Trial Profile

Multimodality Therapy for Recurrent High Risk Prostate Cancer: A Phase II Study.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 01 Mar 2016

At a glance

  • Drugs Docetaxel (Primary) ; Prednisone (Primary) ; Sunitinib (Primary)
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 11 Feb 2014 Planned End Date changed from 1 Apr 2015 to 1 Sep 2015 as reported by ClinicalTrials.gov.
    • 16 Apr 2012 Actual patient number 37 added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top